| Bioactivity | Gavestinel (GV 150526) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pKi of 8.5. Gavestinel can be used for the research of acute ischemic stroke[1]. |
| Target | pKi: 8.5 (NMDA receptor) |
| Name | Gavestinel sodium salt |
| CAS | 153436-38-5 |
| Formula | C18H11Cl2N2NaO3 |
| Molar Mass | 397.19 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Fabio RD, et, al. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem. 1997 Mar 14;40(6):841-50. |
Gavestinel sodium salt
CAS: 153436-38-5 F: C18H11Cl2N2NaO3 W: 397.19
Gavestinel (GV 150526) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.